Premium
Recent developments in immunotherapy of cancers caused by human papillomaviruses
Author(s) -
Fakhr Elham,
Modic Živa,
CidArregui Angel
Publication year - 2021
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/imm.13285
Subject(s) - immunotherapy , medicine , cervical cancer , cancer , clinical trial , hpv vaccines , adjuvant , immunology , head and neck cancer , cancer immunotherapy , immune system , radiation therapy , cancer research , oncology , hpv infection
A subset of oncogenic human papillomaviruses (HPVs) is the main cause of genital cancers, most importantly cervical cancer and an increasing number of head and neck cancers. Despite the availability of prophylactic vaccines against the most prevalent oncogenic HPV types, HPV‐induced malignancies are still a major health and economic burden. Besides conventional treatment with surgery, chemotherapy and radiation, immunotherapy is emerging as an efficient adjuvant option. Here, we review relevant studies and ongoing clinical trials using immune checkpoint inhibitors, therapeutic vaccines, gene editing approaches and adoptive T cell therapies, with special focus on engineered TCR T cells, which are showing encouraging results and could lead to significant improvement in the treatment of HPV+‐infected cancer patients.